205 related articles for article (PubMed ID: 31895884)
1. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction.
Tauber J
Cornea; 2020 Apr; 39(4):403-407. PubMed ID: 31895884
[TBL] [Abstract][Full Text] [Related]
2. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
3. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
Tong AY; Passi SF; Gupta PK
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
[TBL] [Abstract][Full Text] [Related]
5. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
6. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
[TBL] [Abstract][Full Text] [Related]
7. Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model.
Singh PP; Yu C; Mathew R; Perez VL; Saban DR
Ocul Surf; 2021 Jul; 21():271-278. PubMed ID: 33812087
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Management of MGD with Vectored Thermal Pulsation before Cataract Surgery: A Prospective, Controlled Clinical Trial.
Zhao Y; Li J; Xue K; Xie J; Xie G; Gu S; Zhao Y
Semin Ophthalmol; 2021 Feb; 36(1-2):2-8. PubMed ID: 33587674
[No Abstract] [Full Text] [Related]
9. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Therapeutic Meibomian Glands Expression on Evaporative Dry Eye: A Prospective Randomized Controlled Trial.
Kaiserman I; Rabina G; Mimouni M; Sadi Optom NB; Duvdevan N; Levartovsky S; Ben David D
Curr Eye Res; 2021 Feb; 46(2):195-201. PubMed ID: 32602744
[TBL] [Abstract][Full Text] [Related]
12. Long-Term (3 Year) Effects of a Single Thermal Pulsation System Treatment on Meibomian Gland Function and Dry Eye Symptoms.
Greiner JV
Eye Contact Lens; 2016 Mar; 42(2):99-107. PubMed ID: 26222095
[TBL] [Abstract][Full Text] [Related]
13. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
[TBL] [Abstract][Full Text] [Related]
14. A single LipiFlow® Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months.
Greiner JV
Curr Eye Res; 2012 Apr; 37(4):272-8. PubMed ID: 22324772
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.
Finis D; Hayajneh J; König C; Borrelli M; Schrader S; Geerling G
Ocul Surf; 2014 Apr; 12(2):146-54. PubMed ID: 24725326
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety evaluation of a single thermal pulsation system treatment (Lipiflow
Meng Z; Chu X; Zhang C; Liu H; Yang R; Huang Y; Zhao S
Int Ophthalmol; 2023 Apr; 43(4):1175-1184. PubMed ID: 36112256
[TBL] [Abstract][Full Text] [Related]
17. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment.
Greiner JV
Clin Exp Ophthalmol; 2013 Aug; 41(6):524-30. PubMed ID: 23145471
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trial of Thermal Pulsation (LipiFlow) in Meibomian Gland Dysfunction With Preteatment Meibography.
Zhao Y; Veerappan A; Yeo S; Rooney DM; Acharya RU; Tan JH; Tong L;
Eye Contact Lens; 2016 Nov; 42(6):339-346. PubMed ID: 26825281
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: a randomized trial.
Satitpitakul V; Ratanawongphaibul K; Kasetsuwan N; Reinprayoon U
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1289-1294. PubMed ID: 31011823
[TBL] [Abstract][Full Text] [Related]
20. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Keating GM
Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
